The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Open accessAbstract
Modern drug delivery technology began in 1952 with the advent of the Spansule® sustained-release capsule technology, which can deliver a drug for 12 hours after oral administration through an initial immediate dose followed by the remaining released gradually. Until the 1980s, oral and transdermal formulations providing therapeutic durations up to 24 hours for small molecules dominated the drug delivery field and the market. The introduction of Lupron Depot® in 1989 opened the door for long-acting injectables and implantables, extending the drug delivery duration from days to months and occasionally years. Notably, the new technologies allowed long-term delivery of peptide and protein drugs, although limited to parenteral administration. The introduction of the first PEGylated protein, Adagen®, in 1990 marked the new era of PEGylation, resulting in Doxil® (doxorubicin in PEGylated liposome) in 1995, Movantik (PEGylated naloxone - naloxegol) in 2014, and Onpattro® (Patisiran - siRNA in PEGylated lipid nanoparticle) in 2018. Drug-polymer complexes were introduced, e.g., InFed® (iron-dextran complex injection) in 1974 and Abraxane® (paclitaxel-albumin complex) in 2005. In 2000, both Mylotarg™ (antibody-drug conjugate – gemtuzumab ozogamicin) and Rapamune® (sirolimus nanocrystal formulation) were introduced. The year 2000 also marked the launching of the National Nanotechnology Initiative by the U.S. government, which was soon followed by the rest of the world. Extensive work on nanomedicine, particularly formulations designed to escape from endosomes after being taken by tumor cells, along with PEGylation technology, ultimately resulted in the timely development of lipid nanoparticle formulations for COVID-19 vaccine delivery in 2020. While the advances in drug delivery technologies for the last seven decades are breathtaking, they are only the tip of an iceberg of technologies that have yet to be utilized in an approved formulation or even to be discovered. As life expectancy continues to increase, more people require long-term care for various diseases. Filling the current and future unmet needs requires innovative drug delivery technologies to overcome age-old familiar hurdles, e.g., improving water-solubility of poorly soluble drugs, overcoming biological barriers, and developing more efficient long-acting depot formulations. The lessons learned from the past are essential assets for developing future drug delivery technologies implemented into products. As the development of COVID-19 vaccines demonstrated, meeting the unforeseen crisis of the uncertain future requires continuous cumulation of failures, knowledge, and technologies. Conscious efforts of supporting diversified research topics in the drug delivery field are urgently needed more than ever.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“mRNA vaccines for Zika virus and cancer were already in human studies when COVID-19 started [160,161], and the robustness and versatility of mRNA-based vaccine technology allowed the fast production of COVID-19 vaccines.”
BackgroundAdherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Self-citationBangham, A. D., & Horne, R. W. (1964) · Journal of Molecular Biology · doi:10.1016/s0022-2836(64)80115-7 · Cited by 1,809
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Lipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094 · cited 1×
“A drug-polymer conjugate is a polymeric carrier having covalently bound drug molecules [61,62].”
BackgroundModified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Evaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744
Mechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Self-citationThe role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Greco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
Virus treatment questioned after gene therapy death
Lehrman, S. (1999) · Nature · doi:10.1038/43977 · Cited by 576
The tangled history of mRNA vaccines
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-02483-w · Cited by 542
PEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
Materials for oral delivery of proteins and peptides
Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 520
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 488
Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine
Valent, P., Groner, B., Schumacher, U., Superti-Furga, G., Busslinger, M., Kralovics, R., Zielinski, C., Penninger, J. M., Kerjaschki, D., Stingl, G., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000443526 · Cited by 409
Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation
Park, K., Skidmore, S., Hadar, J., Garner, J., Park, H., Otte, A., Soh, B. K., Yoon, G., Yu, D., Yun, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.003 · Cited by 404
Self-citationCytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387
Controlled Drug Delivery: Historical perspective for the next generation
Yun, Y. H., Lee, B. K., & Park, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.005 · Cited by 378
Self-citationLipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 366
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
Enzyme entrapment in liposomes
Gregoriadis, G., Leathwood, P. D., & Ryman, B. E. (1971) · FEBS Letters · doi:10.1016/0014-5793(71)80109-6 · Cited by 331
Breaking Down the Barriers to Precision Cancer Nanomedicine
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330
Scharp, D. W., & Marchetti, P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.018 · Cited by 314 · cited 1×
“This type of delivery system is essential for insulin delivery because insulin needs to be delivered in an exact amount and at the right time as the glucose concentration in the blood fluctuates [10].”
BackgroundCULLIS, P. R., & HOPE, M. J. (1978) · Nature · doi:10.1038/271672a0 · Cited by 305
Gastric Retentive Drug-Delivery Systems
Park, K., Park, H., & Hwang, S.-J. (1998) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v15.i3.20 · Cited by 303
Self-citationRole of nanotechnology behind the success of mRNA vaccines for COVID-19
Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., Chhabra, D., Joshi, K., & Bharani, K. K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101142 · Cited by 284
Ruge, C. A., Kirch, J., & Lehr, C.-M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70072-9 · Cited by 280
Davis, F. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00021-2 · Cited by 278
Micro and nanoscale technologies in oral drug delivery
Ahadian, S., Finbloom, J. A., Mofidfar, M., Diltemiz, S. E., Nasrollahi, F., Davoodi, E., Hosseini, V., Mylonaki, I., Sangabathuni, S., Montazerian, H., et al. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.012 · Cited by 268
Roles of lipid polymorphism in intracellular delivery
Hafez, I. M., & Cullis, P. R. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00103-x · Cited by 266
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Kumthekar, P., Tang, S.-C., Brenner, A. J., Kesari, S., Piccioni, D. E., Anders, C., Carrillo, J., Chalasani, P., Kabos, P., Puhalla, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3258 · Cited by 250
Akhtar, A., Andleeb, A., Waris, T. S., Bazzar, M., Moradi, A.-R., Awan, N. R., & Yar, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.021 · Cited by 240
Encapsulation state of messenger RNA inside lipid nanoparticles
Brader, M. L., Williams, S. J., Banks, J. M., Hui, W. H., Zhou, Z. H., & Jin, L. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.03.012 · Cited by 236
Introduction and overview of peptide and protein pegylation
(2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00020-0 · Cited by 235
Getting Drugs Across Biological Barriers
Yang, R., Wei, T., Goldberg, H., Wang, W., Cullion, K., & Kohane, D. S. (2017) · Advanced Materials · doi:10.1002/adma.201606596 · Cited by 234
Novel Drug Delivery Systems: An Overview of Their Impact on Clinical Pharmacokinetic Studies
Banerjee, P. S., & Robinson, J. R. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199120010-00001 · Cited by 222
Paving the Road for RNA Therapeutics
Dammes, N., & Peer, D. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.004 · Cited by 218
Non-viral COVID-19 vaccine delivery systems
Park, K. S., Sun, X., Aikins, M. E., & Moon, J. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.008 · Cited by 212
Self-citationDrug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies
Escudé Martinez de Castilla, P., Tong, L., Huang, C., Sofias, A. M., Pastorin, G., Chen, X., Storm, G., Schiffelers, R. M., & Wang, J.-W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.011 · Cited by 208
Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery
Deprez, J., Lajoinie, G., Engelen, Y., De Smedt, S. C., & Lentacker, I. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.015 · Cited by 207
Recent Advances in Ocular Drug Delivery Systems
Kuno, N., & Fujii, S. (2011) · Polymers · doi:10.3390/polym3010193 · Cited by 202
Duncan, R., Kopečková-Rejmanová, P., Strohalm, J., Hume, I., Cable, H., Pohl, J., Lloyd, J., & Kopeček, J. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.33 · Cited by 171
Biological barriers to cellular delivery of lipid-based DNA carriers
Bally, M. B., Harvie, P., Wong, F. M. P., Kong, S., Wasan, E. K., & Reimer, D. L. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00034-4 · Cited by 170
Vinarov, Z., Abrahamsson, B., Artursson, P., Batchelor, H. K., Berben, P., Bernkop‐Schnürch, A., Butler, J., Ceulemans, J., Davies, N. M., Dupont, D., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.001 · Cited by 168
Target specific tight junction modulators
Brunner, J., Ragupathy, S., & Borchard, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.008 · Cited by 165
Nanocrystals: a perspective on translational research and clinical studies
Jarvis, M., Krishnan, V., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10122 · Cited by 162
Overcoming key biological barriers to cancer drug delivery and efficacy
Kim, S. M., Faix, P. H., & Schnitzer, J. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.016 · Cited by 161
Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions
Ng’uni, T., Chasara, C., & Ndhlovu, Z. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590780 · Cited by 160
Advanced drug delivery 2020 and beyond: Perspectives on the future
Bae, Y. H., & Park, K. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.018 · Cited by 159
Self-citationCell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer
Khan, M. M., Filipczak, N., & Torchilin, V. P. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.028 · Cited by 159
Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
Makwana, V., Karanjia, J., Haselhorst, T., Anoopkumar‐Dukie, S., & Rudrawar, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120117 · Cited by 159
The past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 159
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
Dammes, N., Goldsmith, M., Ramishetti, S., Dearling, J. L. J., Veiga, N., Packard, A. B., & Peer, D. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00928-x · Cited by 159
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Modulation of Membrane Fusion by Asymmetric Transbilayer Distributions of Amino Lipids
Bailey, A. L., & Cullis, P. R. (1994) · Biochemistry · doi:10.1021/bi00208a007 · Cited by 146
Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles
Xu, E., Saltzman, W. M., & Piotrowski-Daspit, A. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.038 · Cited by 144
Liposomes as agents of DNA transfer
Smith, J. G., Walzem, R. L., & German, J. B. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(93)90004-8 · Cited by 135
Ultrasound-responsive polymersomes capable of endosomal escape for efficient cancer therapy
Wei, P., Sun, M., Yang, B., Xiao, J., & Du, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.013 · Cited by 130
The in vivo fate of nanocrystals
Lü, Y., Qi, J., Dong, X., Zhao, W., & Wu, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.003 · Cited by 127
Safety of intravenous iron formulations: facts and folklore.
Auerbach, M., & Macdougall, I. C. (2014) · PubMed · doi:10.2450/2014.0094-14 · Cited by 122
Park, K., Otte, A., Sharifi, F. J., Garner, J., Skidmore, S., Park, H., Jhon, Y. K., Qin, B., & Wang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.044 · Cited by 121
Self-citationAbdelkader, H., Fathalla, Z. M. A., Seyfoddin, A., Farahani, M., Thrimawithana, T. R., Allahham, A., Alani, A. W. G., Al-Kinani, A. A., & Alany, R. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113957 · Cited by 121
Use of parenteral iron products and serious anaphylactic‐type reactions
Wysowski, D. K., Swartz, L., Borders‐Hemphill, V., Goulding, M. R., & Dormitzer, C. M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21794 · Cited by 118
Quintana, D. S., Guastella, A. J., Westlye, L. T., & Andreassen, O. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.166 · Cited by 107
Peppas, N. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.040 · Cited by 105
Elia, U., Ramishetti, S., Rosenfeld, R., Dammes, N., Bar‐Haim, E., Naidu, G. S., Makdasi, E., Yahalom-Ronen, Y., Tamir, H., Paran, N., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10180 · Cited by 103
Vaccinology in the post−COVID-19 era
Rappuoli, R., Gregorio, E. D., Giudice, G. D., Phogat, S. K., Pecetta, S., Pizza, M., & Hanon, E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020368118 · Cited by 101
Liposomes in Drug Delivery: How It All Happened
Gregoriadis, G. (2016) · Pharmaceutics · doi:10.3390/pharmaceutics8020019 · Cited by 98
DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade
Giri, M. S., Ugen, K. E., & Weiner, D. B. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.370-389.2004 · Cited by 95
Intravenous iron therapy: how far have we come?
Cançado, R. D., & Muñoz, M. (2011) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20110123 · Cited by 94
Phosphodiester models for cleavage of nucleic acids
Mikkola, S., Lönnberg, T., & Lönnberg, H. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.68 · Cited by 89
Chen, W., Yao, S., Wan, J., Tian, Y., Huang, L., Wang, S., Akter, F., Wu, Y., Yao, Y., & Zhang, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.029 · Cited by 83
Byrne, J. D., Huang, H., McRae, J. C., Babaee, S., Soltani, A., Becker, S., & Traverso, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113926 · Cited by 81
Tang, M., Svirskis, D. M., Leung, E. Y., Kanamala, M., Wang, H., & Wu, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.018 · Cited by 79
Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes
Veiga, N., Diesendruck, Y., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.002 · Cited by 79
Pozzi, S., Scomparin, A., Dangoor, S. I., Ajamil, D. R., Ofek, P., Neufeld, L., Krivitsky, A., Vaskovich‐Koubi, D., Kleiner, R., Dey, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.001 · Cited by 79
The drug delivery field at the inflection point: Time to fight its way out of the egg
Park, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.030 · Cited by 74
Self-citationInvestigation of the Cause of Death in a Gene-Therapy Trial
Frank, K. M., Hogarth, D. K., Miller, J. L., Mandal, S., Mease, P. J., Samulski, R. J., Weisgerber, G. A., & Hart, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0801066 · Cited by 72
Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments
Castro, F., Martins, C., Silveira, M. J., Moura, R. P., Pereira, C. L., & Sarmento, B. F. C. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.001 · Cited by 72
Hydrolysis of Esters of Monoribonucleotides
Brown, D. M., Magrath, D. I., NEILSON, A. H., & Todd, A. R. (1956) · Nature · doi:10.1038/1771124a0 · Cited by 70
To PEGylate or not to PEGylate, that is not the question
Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.025 · Cited by 70
Self-citationBiomedical nanoparticle design: What we can learn from viruses
Figueroa, S. M., Fleischmann, D., & Göpferich, A. M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.045 · Cited by 68
Use of adenovirus type-5 vectored vaccines: a cautionary tale
Buchbinder, S., McElrath, M. J., Dieffenbach, C. W., & Corey, L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32156-5 · Cited by 65
Henrich‐Noack, P., Nikitovic, D., Neagu, M. T., Docea, A. O., Engin, A. B., Gelperina, S. E., Штильман, М. И., Mitsias, P. D., Tzanakakis, G. N., Gozes, I., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.01.016 · Cited by 64
Skidmore, S., Hadar, J., Garner, J., Park, H., Park, K., Wang, Y., & Jiang, X. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.002 · Cited by 64
Self-citationFattah, S., Ismaiel, M., Murphy, B. P., Rulikowska, A., Frías, J. M., Winter, D. C., & Brayden, D. J. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105509 · Cited by 60
Fourth Boy Dies in Clinical Trial of Astellas' AT132
Philippidis, A. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29182.bfs · Cited by 59
Blood-brain barrier models: Rationale for selection
Hanafy, A. S., Dietrich, D., Fricker, G., & Lamprecht, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113859 · Cited by 58
High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?
Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008030255 · Cited by 56
Challenges and strategies for the delivery of biologics to the cornea
Wels, M., Roels, D., Raemdonck, K., Smedt, S. C. D., & Sauvage, F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.008 · Cited by 56
Biomimetic and cell-based nanocarriers – New strategies for brain tumor targeting
Mendanha, D., de Castro, J. V., Ferreira, H., & Neves, N. M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.047 · Cited by 55
Lee, J. H., Hu, J. K., Georgeson, E., Nakao, C., Gröschel, B., Dileepan, T., Jenkins, M. K., Seumois, G., Vijayanand, P., Schief, W. R., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201254 · Cited by 53
Gautam, N., McMillan, J., Kumar, D., Bade, A. N., Pan, Q., Kulkarni, T. A., Li, W., Sillman, B., Smith, N. A., Shetty, B. L. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23668-x · Cited by 50
The Power of Noticing: What the Best Leaders See
(2014) · Cited by 44
Shander, A., Spence, R. K., & Auerbach, M. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02492.x · Cited by 41
What Has 30 Years of HIV Vaccine Research Taught Us?
Esparza, J. (2013) · Vaccines · doi:10.3390/vaccines1040513 · Cited by 32
Clinical translation of immunomodulatory therapeutics
Nash, A., Aghlara-Fotovat, S., Hernández, A., Scull, C. M., & Omid Veiseh, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113896 · Cited by 32
Ito, S., Torii, Y., Chikamatsu, S., Harada, T., Yamaguchi, S., Ogata, S., Sonoda, K., Wakayama, T., Masuda, T., & Ohtsuki, S. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01010 · Cited by 22
Impact of anti-PEG antibodies on PEGylated nanoparticles fate in vivo
Park, K. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.014 · Cited by 20
Self-citationHoffman, A. S., & Lai, J. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.013 · Cited by 19
Historical Introduction to the Field of Controlled Drug Delivery
(2016) · CRC Press eBooks · doi:10.1201/9781315382579-2 · Cited by 12
Liu, X., Anissimov, Y. G., Grice, J. E., Cheruvu, H. S., Ghosh, P., Raney, S. G., Maïbach, H. I., & Roberts, M. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.010 · Cited by 10
Are controlled release scientists doing enough for our environment?
Park, K., & Mrsny, R. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.012 · Cited by 7
Self-citation
Research works printed but not linked: 12
- Ullyot, 2000, The metamorpohsis of Smith-Kline & French Laboratories to Smith Kline Beecham: 1925-1998, Bull. Hist. Chem., 25, 16, 10.70359/bhc2000v025p016 · doi:10.70359/bhc2000v025p016
- Liu, 1984, Comparative release of phenylpropanolamine HCl from long-acting appetite suppressant products: Acutrim vs, Dexatrim. Drug Develop. and Indus. Pharm., 10, 1639, 10.3109/03639048409039072 · doi:10.3109/03639048409039072
- Davis, 1979, Non-immunogenic polypeptides, 4, 337
- Ellory, 2010, AD Bangham (1922-2010), Physiology News, 79, 55
- Wu, 2020, Drug development through modification of small molecular drugs with Monodisperse poly(ethylene glycol)s, Org. Process. Res. Dev., 24, 1364, 10.1021/acs.oprd.0c00273 · doi:10.1021/acs.oprd.0c00273
- Lawrence, 1998, Development and comparison of iron dextran products, PDA J. Pharm. Sci. Technol., 52, 190
- Morrow, 2010, DNA drugs come of age, Sci. Am., 49
- Lindsley, 2011, The top prescription drugs of 2010 in the United States: antipsychotics show strong growth, ACS Chem. Neurosci., 2, 276, 10.1021/cn200050c · doi:10.1021/cn200050c
- Israeli, 1998, Paul Ehrlich's ingredients for success, Lancet, 352, 1712, 10.1016/S0140-6736(05)61497-3 · doi:10.1016/s0140-6736(05)61497-3
- FDA/CDER, 2000, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification, System
- Chaplin, 2020, Rybelsus: an oral formulation of the GLP-1 agonist semaglutide, Prescriber, 31, 32
- Li, 2019, Fabrication of gradient porous microneedle array by modified hot embossing for transdermal drug delivery, Mater. Sci. Eng. C, 96, 576, 10.1016/j.msec.2018.11.074 · doi:10.1016/j.msec.2018.11.074
Cited by
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Bi, Y., Chen, J., Li, Q., Li, Y., Zhang, L., Zhida, L., Yuan, F., & Zhang, R. (2024) · iScience · doi:10.1016/j.isci.2024.108833 · Cited by 24
Metadata
- Authors
- Park, H., Otte, A., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 342
- Pages
- 53-65
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4200575452
- Cited by
- 475
- References
- 121
- FWCI
- 20.60
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Institute on Drug Abuse
- Ralph W. and Grace M. Showalter Research Trust Fund
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.